NEOANTIGEN VACCINES KEEP CANCER FROM COMING BACK.
- Resource Type
- Article
- Authors
- MILLER, KENNETH
- Source
- Discover. Jan/Feb2024, Vol. 45 Issue 1, p30-31. 2p. 4 Color Photographs.
- Subject
- *CANCER vaccines
*PANCREATIC cancer
*CANCER cells
*CLINICAL trials
*IMMUNE response
- Language
- ISSN
- 0274-7529
Two clinical trials in 2023 showed promising results for a new generation of cancer vaccines. One trial focused on melanoma patients and found that an experimental therapeutic vaccine reduced the risk of recurrence by 44% compared to standard therapy. The vaccine targets neoantigens, which are unique to an individual's cancer cells. Another trial focused on pancreatic cancer and used personalized mRNA vaccines tailored to each patient, resulting in an immune response in half of the cases and no recurrence in the responders. While more research is needed, these results are encouraging for the future of cancer vaccines. [Extracted from the article]